🇺🇸 FDA
Patent

US 7452879

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

granted A61KA61K31/506A61K31/538

Quick answer

US patent 7452879 (Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds) held by Rigel Pharmaceuticals, Inc. expires Mon Nov 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Nov 18 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 13 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K31/506, A61K31/538, A61K31/541, A61P